Novartis India Ltd Upgraded to Hold as Technicals Improve Despite Valuation Concerns

Technical Trends Drive Upgrade

The primary catalyst for the upgrade to a Hold rating is the marked improvement in Novartis India’s technical profile. The technical grade shifted from mildly bullish to bullish, supported by a series of positive momentum indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) and Bollinger Bands signal bullish momentum, while the monthly MACD and Bollinger Bands also confirm this trend. The daily moving averages remain bullish, reinforcing short-term strength.

Other technical metrics such as the Know Sure Thing (KST) indicator show a weekly bullish stance and a mildly bullish monthly trend. The Dow Theory readings are mildly bullish on both weekly and monthly timeframes, suggesting a sustained upward trend. Although the Relative Strength Index (RSI) is neutral weekly and bearish monthly, the overall technical picture favours a positive outlook. The On-Balance Volume (OBV) indicator is bullish monthly, indicating accumulation by investors over the longer term.

This technical improvement coincides with a strong price performance, with the stock closing at ₹1,182.95 on 11 May 2026, up 6.32% on the day and reaching a 52-week high of ₹1,243.60. The stock’s recent price action reflects growing investor confidence, justifying the upgrade in technical grade and the overall rating.

Valuation: Very Expensive but Reflective of Growth Potential

While the technical outlook has improved, Novartis India’s valuation grade has been downgraded from expensive to very expensive. The company currently trades at a price-to-earnings (PE) ratio of 29.74, which is high relative to many peers in the Pharmaceuticals & Biotechnology sector. Its price-to-book value stands at 3.73, and the enterprise value to EBITDA ratio is 23.39, both indicating a premium valuation.

The PEG ratio of 2.34 suggests that the stock’s price growth is outpacing earnings growth, which has been moderate at 12.7% over the past year. Despite this, the company’s return on capital employed (ROCE) is an impressive 60.87%, and return on equity (ROE) is 12.54%, signalling efficient use of capital and shareholder funds. The dividend yield remains modest at 2.13%, reflecting a balance between reinvestment and shareholder returns.

Compared to peers such as Ajanta Pharma (PE 36.08) and J B Chemicals (PE 47.18), Novartis India’s valuation is relatively more reasonable, though still on the higher side. This premium is justified by its strong operational metrics and market-beating returns, but investors should be cautious given the stretched multiples.

Financial Trend: Mixed Signals Amidst Profit Declines

Novartis India’s recent financial performance presents a mixed picture. The company reported a decline in quarterly profit after tax (PAT) to ₹16.09 crores, down 36.8% year-on-year for Q3 FY25-26. Profit before tax excluding other income (PBT less OI) also fell by 15.35% to ₹20.90 crores. Additionally, the debtors turnover ratio for the half-year period dropped to 7.28 times, indicating slower collection efficiency.

Despite these short-term setbacks, the company remains net-debt free, which is a significant strength in a capital-intensive sector. Operating profit has grown at an annualised rate of 57.68%, underscoring healthy long-term growth potential. The stock’s total returns have been exceptional, with a 47.11% gain over the past year and 75.82% over three years, far outpacing the Sensex’s respective returns of -4.33% and 22.79% over the same periods.

This divergence between recent profit declines and strong long-term growth metrics suggests that the company is navigating short-term challenges while maintaining a solid foundation for future expansion.

Technical and Market Performance: Outperforming Benchmarks

Novartis India’s stock performance has been remarkable relative to broader market indices. Over the past week, the stock surged 15.76%, while the Sensex declined 1.62%. Over one month, the stock gained 18.23% against a 1.98% fall in the Sensex. Year-to-date, the stock has returned 51.85%, contrasting sharply with the Sensex’s negative 10.80% return.

Longer-term returns also highlight the company’s outperformance, with 5-year returns of 82.08% compared to the Sensex’s 54.62%. Even over a decade, Novartis India has delivered 64.30% returns, though this trails the Sensex’s 196.97%, reflecting the company’s smaller market capitalisation and sector-specific dynamics.

These returns have been achieved despite the company’s relatively small presence in domestic mutual fund portfolios, which hold only 0.01% of the stock. This limited institutional interest may reflect concerns over valuation or business fundamentals, but also suggests potential for increased investor participation if the company continues to demonstrate growth and stability.

Quality Assessment: Balanced but Cautious

Novartis India’s quality metrics reflect a company with strong operational efficiency but facing some near-term challenges. The company’s net-debt-free status is a key positive, reducing financial risk and providing flexibility for growth initiatives. The robust ROCE of 60.87% indicates effective capital utilisation, while the ROE of 12.54% is respectable but not outstanding.

However, the recent quarterly profit decline and slower debtor turnover ratio highlight areas requiring attention. The company’s ability to sustain its operating profit growth rate of 57.68% annually will be critical to maintaining its quality rating. Investors should monitor upcoming quarterly results closely to assess whether the recent profit dip is a temporary setback or indicative of deeper operational issues.

Conclusion: Hold Rating Reflects Improved Technicals Amid Valuation Caution

The upgrade of Novartis India Ltd’s investment rating from Sell to Hold is primarily driven by a significant improvement in technical indicators and strong long-term price performance. The bullish weekly and monthly technical signals, combined with market-beating returns over one, three, and five years, support a more optimistic outlook.

Nevertheless, the company’s very expensive valuation and recent quarterly profit declines temper enthusiasm. The stock trades at a premium relative to peers, and the PEG ratio suggests that price appreciation has outpaced earnings growth. The net-debt-free balance sheet and healthy operating profit growth provide a solid foundation, but investors should remain cautious given the mixed financial trends.

Overall, the Hold rating reflects a balanced view: Novartis India is no longer a sell, but valuation and near-term profit concerns prevent a more bullish stance. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may consider Novartis India as a stable, technically supported option, while monitoring financial performance closely.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →